T1	Intervention 0 156	Randomized, double-blind, multicenter trial comparing two doses of arzoxifene (LY353381) in hormone-sensitive advanced or metastatic breast cancer patients.
T2	Intervention 714 723	according
T3	Intervention 1257 1297	There were no study drug-related deaths.
T4	Intervention 463 514	Pharmacokinetics and toxicities were also assessed.
